OSLO/LONDON, JANUARY 26th 2021: EXACT THERAPEUTICS AS ("EXACT-Tx" or the
"Company"), a clinical stage precision medicine company utilizing Acoustic
Cluster Therapy (ACT®) across multiple therapeutic areas, today announced the
appointment of Dr Hilary McElwaine-Johnn as Chief Medical Officer. Dr
McElwaine-Johnn will be based at the newly opened London office of EXACT-Tx at
the Translation & Innovation Hub (i-Hub) at White City.  

"We are delighted to welcome Hilary to EXACT Therapeutics AS where her unique
experience in both therapeutics and drug delivery complemented by deep medical
expertise will be pivotal in driving forward the development of ACT®, both in
the ongoing Phase I ACTIVATE study and beyond", said Dr Rafiq Hasan, CEO of
EXACT Therapeutics AS. "Hilary joins EXACT-Tx at an exciting time as we expand
our presence in the UK with the opening of our London office at the White City
i-Hub in close proximity to the growing Imperial College campus". 

Dr McElwaine-Johnn gained her medical degree from Imperial College, London and
is a Member of the Royal College of Physicians and Faculty of Pharmaceutical
Medicine. Following clinical roles in general internal medicine and oncology,
she has pursued a highly successful career in the pharmaceutical industry. She
has held a variety of senior medical positions including Vice President,
Clinical, PowderMed Ltd (which was subsequently acquired by Pfizer), Chief
Medical Officer of Vantia Ltd, PsiOxus Therapeutics Ltd and most recently Karus
Therapeutics. During this time Hilary has gained extensive experience in drug
development in both oncology and other therapeutic indications as well as
delivery technologies complemented by a range of successful interactions with
Regulatory Authorities, partner companies and fundraising activities. 

Dr McElwaine-Johnn commented: "I am excited to be joining EXACT Therapeutics in
London to be part of a dynamic and innovative organization exploring the
potential of the ACT® platform to transform clinical practice across
indications, particularly in the management of patients with cancer.  With a
strong preclinical evidence base and clinical development of ACT® already
underway, I am looking forward to working with the clinical community in further
investigating this exciting approach to ultrasound mediated therapeutic
targeting." 

About ACT®
o ACT® is a proprietary formulation consisting of microbubbles and microdroplets
that are activated through the application of ultrasound with the consequent
increase in targeted delivery of a co-administered therapeutic agent. 
ACT® is supported by a strong and broad preclinical package demonstrating
therapeutic enhancement in multiple oncology models (pancreatic, breast, colon,
prostate) as well as blood-brain barrier penetration.
o Initial focus of the company is oncology, however the ACT® platform has
potential across therapeutic areas (infectious diseases, CNS, immunotherapy) and
product classes.

About EXACT
EXACT-Tx is a clinical stage Norwegian biotech company developing a technology
platform for targeted therapeutic enhancement - Acoustic Cluster Therapy (ACT®).
ACT® sonoporation is a unique approach to ultrasound-mediated, targeted drug
enhancement - with the potential to significantly amplify the clinical utility
of a wide range of therapeutic agents across a multitude of indications
including within oncology (chemotherapy, immunotherapy), infectious diseases,
and neurological conditions. www.exact-tx.com

For more information contact:

Dr Rafiq Hasan, CEO EXACT Therapeutics Rafiq@exact-tx.com

Richard Hayhurst/Janet Joy
Tel +44 7711 821527
richard@rhapr.eu